Holen Sie sich die Stockscreener-App
45.94
0.48%
0.22
Vorhandelsmarkt:
46.34
0.40
+0.87%
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Moderna (MRNA) Prepares for Earnings Amid Revenue Challenges - GuruFocus
Moderna Q1 preview: revenue rebound in focus as losses persist (MRNA:NASDAQ) - Seeking Alpha
Vanguard Capital Management (MRNA) reports 25.9M-share stake (6.53%) - Stock Titan
Moderna in the spotlight: Can pipeline offset earnings decline? By Investing.com - Investing.com Australia
How Will Moderna Stock React To Its Upcoming Earnings? - Trefis
Moderna Stock 5-Day Losing Spree: Stock Falls 18% - Trefis
Discipline and Rules-Based Execution in MRNA Response - Stock Traders Daily
mRNA Treatment Market 2026 | Argos Therapeutics, Inc., CureVac AG, ethris GmbH, Moderna, Inc., Tiba Biotech etc. - openPR.com
Pfizer, BioNTech Defeat Moderna COVID Jab Patent - Law360
Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026 - Yahoo Finance
Leading Companies Fueling Growth and Innovation in the Spikevax Market - openPR.com
Research Analysts Issue Forecasts for Moderna Q1 Earnings - MarketBeat
Salesforce Says Moderna Selects Agentforce Platform to Consolidate Commercial Operations - Moomoo
AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer - BioSpace
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect - Yahoo Finance
Is Moderna (MRNA) Pricing Make Sense After 77% One-Year Surge And DCF Signal? - Yahoo Finance
Moderna Hit With Suit Over CureVac COVID Patents - Law360
Moderna wins full FDA approval for COVID shot in children - MSN
CureVac Patent Suit Targets Moderna’s Spikevax Covid-19 Shots - Bloomberg Law News
Moderna shares dip amid rising selling pressure - Traders Union
Which Is the Better iShares ETF for Small-Cap Value Investing, ISCV or IWN? - The Motley Fool
Moderna, Inc. (MRNA) Stock Analysis: Navigating A 52-Week High Amidst Revenue Decline - DirectorsTalk Interviews
Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Has $4.12 Million Position in Moderna, Inc. $MRNA - MarketBeat
M&T Bank Corp Acquires 240,400 Shares of Moderna, Inc. $MRNA - MarketBeat
MRNA Price Today: Moderna, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate - Eagle-Tribune
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - Cadillac News
CureVac sues Moderna over mRNA vaccine patents - Investing.com
Moderna shares slide as traders digest recent EU vaccine clearance and refocus on funding/earnings overhangs - Quiver Quantitative
CureVac sues Moderna over mRNA vaccine patents By Investing.com - Investing.com Canada
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
MRNA Technical Analysis | Trend, Signals & Chart Patterns | MODERNA INC (NASDAQ:MRNA) - ChartMill
Moderna (MRNA) Expected to Announce Earnings on Friday - MarketBeat
Moderna, Inc. (MRNA) Presents at ESCMID Global 2026Slideshow (NASDAQ:MRNA) 2026-04-23 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
What does smart money think about Moderna (MRNA) stock (+1.11%) 2026-04-22Social Buzz - Cổng thông tin điện tử tỉnh Lào Cai
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
COVID vaccine report on cutting hospital visits blocked from publication in CDC journal - Seeking Alpha
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial - Healthcare Dive
European Commission Approves MRNA's COVID-19-Influenza Combo Shot - Yahoo Finance
Moderna starts late-stage trial for bird flu vaccine - Seeking Alpha
Analyst recommendations: Meta, Amazon, Booking, Goldman Sachs, Moderna… - marketscreener.com
Moderna : ESCMID 2026 (mRNA-1273 & mRNA-1283 Effectiveness and safety of variant updated Covid vaccines) - marketscreener.com
Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot - BioSpace
Moderna Inc. stock (US60770K1034): Does its mRNA pivot beyond COVID now unlock sustainable growth? - AD HOC NEWS
Moderna Inc. (MRNA)Announces Accepted Oncology Clinical Data Presentations at 2026 ASCO Annual Meeting, Schedules Concurrent Investor WebcastFloat Short - UBND thành phố Hải Phòng
Moderna Inc. (MRNA) Secures European Commission Marketing Authorization for World’s First Combined Influenza-COVID mRNA Vaccine mCOMBRIAXCost Structure - UBND thành phố Hải Phòng
Moderna to Present at Upcoming Conferences in May 2026 - Investing News Network
Moderna (MRNA) Advances with Phase 3 Study of Influenza Vaccine - GuruFocus
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
Moderna begins phase 3 trial of H5 bird flu vaccine candidate - Investing.com Canada
Moderna starts late-stage trial of bird flu vaccine in US, UK - Reuters
High-Yield Autocallable Notes Linked to Moderna (AMUB) — 1-Year Term - Stock Titan
Europe Clears First Flu/COVID Combo Shot From Moderna - Benzinga
Moderna Receives European Commission Marketing Authorization For mCOMBRIAX - TradingView
Moderna (MRNA) Secures EU Approval for mCOMBRIAX Vaccine - GuruFocus
Moderna: Ec Granted Marketing Authorization f - Moomoo
Moderna (MRNA) Secures EU Approval for mRNA Combination Vaccine - GuruFocus
Moderna wins EU approval for combined flu, COVID shot for older adults - Reuters
Moderna wins EC nod for mCOMBRIAX - The Pharma Letter
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting - Investing News Network
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):